PharmaCyte Biotech closed at $0.38 on Nov 5, down 1.52%, 69.2% below its 52-week closing high. Volume of 204.1K shares was 1.97× its 20-day average (above normal).
Split-adjusted performance: -7.5% over one month, -53.1% over six months, -57.8% over one year.
Short interest was 70.1K shares at the Oct 15 settlement, down 47.6% from the prior report (0.8% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| PMCBPharmaCyte Biotech | $0.3752 | −1.52% | −53.1% | — | — | — | $4.0M | |
| LIMNLiminatus Pharma | $2.63 | −5.88% | −73.8% | — | — | — | $3.5M | Compare |
| CELZCreative Medical Technology Holdings | $0.6059 | −7.05% | −73.5% | — | — | — | $4.6M | Compare |
| AIMAIM ImmunoTech | $0.1521 | −5.53% | −72.8% | +4.0% | −26876.9% | — | $6.1M | Compare |
| SNTISenti Biosciences Holdings | $0.1645 | −6.85% | −83.3% | — | −75000.0% | — | $6.3M | Compare |
| HLSQTessera Defense and Homeland Security | $0.1241 | −13.82% | — | — | — | — | $2.6M | Compare |
| SLXNSilexion Therapeutics | $0.1438 | −6.32% | −97.2% | — | — | — | $2.1M | Compare |
| CRISCuris | $0.8500 | −23.42% | −92.6% | −100.0% | — | — | $2.1M | Compare |
| INABIN8bio | $0.8300 | −10.82% | −48.1% | — | — | — | $8.2M | Compare |
No recent articles focused on PharmaCyte Biotech.
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
